RESEARCH

RESEARCH IN PULMONARY HYPERTENSION

"PHA's research program has yielded an explosion of understanding about PH that was not known before."
- John Newman, MD, Vanderbilt University Medical Center

Dr. Vallerie McLaughlin
Clinical Trials: What’s on the Horizon for PAH?

Watch Dr. Vallerie McLaughlin’s webinar presentation from July 2009

Twenty years ago there were no pulmonary hypertension treatments available. Through focused research there are now eight PH-specific treatments with more in development. But we know that your ultimate wish is for a cure, and that is why PHA will continue to support the work of researchers until the day when no one suffers from PH.

PHA’s Research Program

In just a little under a decade, PHA’s Research Program has committed almost $9 million for PH research by leveraging partnerships with the National Heart, Lung, and Blood Institute (NHLBI), American Thoracic Society (ATS) and the American Heart Association (AHA). We have supported over 44 promising researchers through three independently reviewed cutting-edge research programs.

Read more about PHA’s Research Program

Learn more

Current Treatments

PHA’s Scientific Leadership Council’s Education Committee has put together comprehensive factsheets on all the treatments available for pulmonary hypertension. Read more about current treatments

Research Corner in Pathlight

Every issue of PHA’s quarterly print newsletter Pathlight features a Research Corner with information about some of the latest research. Read more

Pulmonary Hypertension Research News

Headlines only

Adcirca® (tadalafil) Approved in Canada for PAH Patients
2/3/10 (PharmaLive) - Adcirca® (tadalafil) is now available in Canada for the treatment of pulmonary arterial hypertension (PAH). Adcirca® is the first once-a-day PDE-5 inhibitor oral therapy for the treatment of PAH. It is a vasodilator, which means it relaxes or opens blood vessels. “As a physician who treats this serious and life-threatening disease, I am confident that the convenience of this new oral treatment will help to promote compliance among patients, thus making a difference in their health-related quality of life,” said Dr. Sanjay Mehta, Professor of Medicine and Director of the Southwest Ontario PH Clinic in London, Ontario, and Medical Director, PHA Canada. Read article | Read Tadalafil (Adcirca®) Fact Sheet
Thursday, February 04, 2010 10:58:25 AM

Transcatheter Aortic Valve Replacement in Patients with High Surgical Risk
1/21/10 (Cardiology Today) - Transfemoral and transapical transcatheter aortic valve implantation in patients at prohibitive or high surgical risk were associated with comparable mortality as predicted by surgical risk calculators, results from a study suggested. If there is truth in repetitive data, it looks like transcatheter aortic valve replacement works. Read article
Wednesday, January 27, 2010 3:54:30 PM

Novel Equation Effective at Predicting Survival in Pulmonary Arterial Hypertension
(Cardiology Today) - A newly formed equation that can predict survival in patients with pulmonary arterial hypertension was more effective than the equation traditionally used by the National Institutes of Health to predict survival, study results suggested. Read Article
Friday, January 08, 2010 9:56:00 PM

Researchers Revisit Pulmonary Arterial Hypertension Survival
(EureaAlert) - Setting out to determine the survival of patients with pulmonary arterial hypertension (PAH), researchers at the University of Chicago Medical Center and their colleagues also discovered that an equation used for more than 20 years to predict survival is outdated. Accordingly, they developed and recently published a new survival prediction equation that will impact clinical practice and the drug development process. Read article
Tuesday, January 05, 2010 10:14:00 AM

NeoPharm to Investigate Treatment for Deadly Lung Disease
(onemedplace) - NeoPharm, a biopharmaceutical company specializing in cancer treatments, has filed an investigational new drug application with the U.S. Food and Drug Administration (FDA) for the treatment of a deadly lung disease. The drug candidate IL13-PE has the potential to be the first effective therapy for idiopathic pulmonary fibrosis (IPF), which kills an estimated 40,000 people in the United States each year. Read article
Tuesday, January 05, 2010 10:12:00 AM

Patients & Families

Woman having blood drawn

Participating in research & clinical trials helps provide information vital to progress toward a cure.

Learn more about participating in research

MEDICAL PROFESSIONALS

beakers in a lab

Research grant opportunities are available from PHA’s Research Program in the field of PH.

Learn more and apply today

ADVOCATE FOR RESEARCH FUNDING

Put your Members of Congress to work for you, their constituent. Ask them to support federal funding for PH research and education.

Advocate for PH research funding

PATH TO A CURE

Drs. Benza and Frantz and Jessica Lazar, PA, are climbing Mt. Kilimanjaro to support PHA programs and PH research.

Learn how you can help

Email Updates

Stay informed about current research, events, and more.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

For the best viewing experience of this site, it is recommended that you use Internet Explorer 7 or 8 or Firefox.

© 2010 Pulmonary Hypertension Association. All Rights Reserved.
801 Roeder Road, Ste. 400, Silver Spring, MD 20910 Patient-to-Patient Helpline: 1-800-748-7274
PHA@PHAssociation.org Privacy Policy Provide Feedback & Report Bugs

Created by Matrix Group International, Inc.®